Literature DB >> 10737895

CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.

B J Votta1, J R White, R A Dodds, I E James, J R Connor, E Lee-Rykaczewski, C F Eichman, S Kumar, M W Lark, M Gowen.   

Abstract

We have previously demonstrated that a tartrate-resistant acid phosphatase (TRAP)-positive subpopulation of mononuclear cells isolated from collagenase digests of human osteoclastoma tissue exhibits an osteoclast phenotype and can be induced to resorb bone. Using these osteoclast precursors as a model system, we have assessed the chemotactic potential of 16 chemokines. Three CC chemokines, the recently described CKbeta-8, RANTES, and MIP-1alpha elicited significant chemotactic responses. In contrast, 10 other CC chemokines (MIP-1beta, MCP-1, MCP-2, MCP-3, MCP-4, HCC-1, eotaxin-2, PARC, SLC, ELC) and 3 CXC chemokines (IL-8, GROalpha, SDF-1) were inactive. None of these chemokines showed any chemotactic activity for either primary osteoblasts derived from human bone explants or the osteoblastic MG-63 cell line. The identity of the osteoclast receptor that mediates the chemotactic response remains to be established. However, all three active chemokines have been reported to bind to CCR1 and cross-desensitization studies demonstrate that RANTES and MIP-1alpha can partially inhibit the chemotactic response elicited by CKbeta-8. CKbeta-8, the most potent of the active CC chemokines (EC(max) 0.1-0.3 nM), was further characterized with regard to expression in human bone and cartilage. Although expression is not restricted to these tissues, CKbeta-8 mRNA was shown to be highly expressed in osteoblasts and chondrocytes in human fetal bone by in situ hybridization. In addition, CKbeta-8 protein was shown to be present in human osteophytic tissue by immunolocalization. These observations suggest that CKbeta-8, and perhaps other chemokines, may play a role in the recruitment of osteoclast precursors to sites of bone resorption. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737895     DOI: 10.1002/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.0.CO;2-8

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

Review 1.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

2.  Porphyromonas gingivalis-induced inflammatory mediator profile in an ex vivo human whole blood model.

Authors:  C Bodet; F Chandad; D Grenier
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro.

Authors:  Meiheng Yang; Geneviève Mailhot; Carole A MacKay; April Mason-Savas; Justin Aubin; Paul R Odgren
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

4.  Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daiichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

5.  Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.

Authors:  Akiyoshi Hoshino; Tadahiro Iimura; Satoshi Ueha; Sanshiro Hanada; Yutaka Maruoka; Mitsuori Mayahara; Keiko Suzuki; Toshio Imai; Masako Ito; Yoshinobu Manome; Masato Yasuhara; Takaaki Kirino; Akira Yamaguchi; Kouji Matsushima; Kenji Yamamoto
Journal:  J Biol Chem       Date:  2010-06-22       Impact factor: 5.157

6.  CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Authors:  Daniel J Dairaghi; Babatunde O Oyajobi; Anjana Gupta; Brandon McCluskey; Shichang Miao; Jay P Powers; Lisa C Seitz; Yu Wang; Yibin Zeng; Penglie Zhang; Thomas J Schall; Juan C Jaen
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

7.  Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis.

Authors:  Toshio Takano; Yin-Ji Li; Akiko Kukita; Takayoshi Yamaza; Yasunori Ayukawa; Kanako Moriyama; Norihisa Uehara; Hisayuki Nomiyama; Kiyoshi Koyano; Toshio Kukita
Journal:  Lab Invest       Date:  2014-01-06       Impact factor: 5.662

8.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

9.  Oral inflammatory diseases and systemic inflammation: role of the macrophage.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Immunol       Date:  2012-05-16       Impact factor: 7.561

10.  Human variation in gingival inflammation.

Authors:  Shatha Bamashmous; Georgios A Kotsakis; Kristopher A Kerns; Brian G Leroux; Camille Zenobia; Dandan Chen; Harsh M Trivedi; Jeffrey S McLean; Richard P Darveau
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.